Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 1 […]

Leave a Reply

Your email address will not be published.

Previous post Analysts Set Hudbay Minerals Inc. (TSE:HBM) PT at C$9.27
Next post Southwestern Energy (NYSE:SWN) Given Average Recommendation of “Hold” by Analysts